PRPO logo.png
Clinical Validations for IV-Cell™ and HemeScreen™ Completed
26 sept. 2019 10h53 HE | Precipio, Inc.
 Orders expected from several major labs both domestically and internationally NEW HAVEN, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO),...
NTS Ventures and IHMA Announce a Significant and Important Program Focusing on Antifungal Resistance Surveillance: STAR (Susceptibility Trends in Antifungal Resistance)
12 juin 2019 08h00 HE | IHMA Inc
SCHAUMBURG, Ill., June 12, 2019 (GLOBE NEWSWIRE) -- NTS Ventures (NTS), a mycology and antifungal clinical research laboratory and International Health Management Associates, Inc./IHMA Europe Sàrl...
PRPO logo.png
Precipio Signs First Major International Services Contract
29 avr. 2019 08h35 HE | Precipio, Inc.
NEW HAVEN, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has signed a services contract with a health care...
PRPO logo.png
Precipio’s HemeScreen™ Adopted by Methodist Health
03 avr. 2019 07h38 HE | Precipio, Inc.
NEW HAVEN, Conn., April 03, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that Methodist Hospital, located in Memphis, TN, has selected...
PRPO logo.png
Precipio Expands ICE COLD-PCR™ Menu for Breast, Colon and Endometrial Cancers
23 oct. 2018 09h15 HE | Precipio, Inc.
Ultra-sensitive assays for PIK3CA exons 9 & 20 detect mutations that impact critical therapeutic decisions NEW HAVEN, Conn., Oct. 23, 2018 (GLOBE NEWSWIRE) --  Precipio, Inc. (NASDAQ: PRPO),...
PRPO logo.png
Precipio Launches HemeScreen™, a Disruptive, Proprietary Molecular Test for Hematologic Cancers
03 oct. 2018 07h47 HE | Precipio, Inc.
Impacts a $100M annual US laboratory market by reducing testing costs through a simple, screening assay NEW HAVEN, Conn., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company...
HiberGene Completes Group B Streptococcus Study with National Maternity Hospital
12 janv. 2017 04h15 HE | HiberGene Diagnostics Ltd
DUBLIN, Ireland, Jan. 12, 2017 (GLOBE NEWSWIRE) -- A joint study conducted by Dublin-based molecular diagnostics manufacturer HiberGene and the National Maternity Hospital (NMH), Dublin has found...
HiberGene Launches HG C. Difficile Test
15 déc. 2016 04h55 HE | HiberGene Diagnostics Ltd
DUBLIN, Ireland, Dec. 15, 2016 (GLOBE NEWSWIRE) -- HiberGene Diagnostics, a company focussed on applying molecular technology to the infectious disease segment of the diagnostics market, has...
Breakthrough Technology Spurs New Test for Non-Small Cell Lung Cancer Patients
05 nov. 2015 15h18 HE | ARUP Laboratories
SALT LAKE CITY, Nov. 5, 2015 (GLOBE NEWSWIRE) -- For a patient battling lung cancer, the discomforts and risks of undergoing repeated biopsies, surgeries, and radiologic scans can now be replaced by a...
Molecular Imaging Agents: Targets, Technology, Markets, and Commercial Opportunities
08 nov. 2013 10h07 HE | Research and Markets
Dublin, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Research and Markets ( has announced the addition of the "Molecular Imaging...